Temperature-Stable TB Vaccine Safe, Prompts Immune Response in NIH-Supported Study

National Institute of Allergy and Infectious Diseases sent this bulletin at 03/06/2023 02:41 PM EST

Monday, March 6, 2023

Temperature-Stable TB Vaccine Safe, Prompts Immune Response in NIH-Sponsored Study

Scanning electron micrograph of Mycobacterium tuberculosis bacteria

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by NIAID. A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. Results are published in Nature Communications.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).